Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 13.60 as of 2026-10-06T18:32:48.716Z.
Consensus retrieved: 2026-10-06T15:52:43.229Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T18:32:48.716Z.
Quote observation: 2026-10-06T18:30:06.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 10184983b4f7142f96f0067605243f392fc8fcbd70b0fec7dfdf58ff773dff78
Forward PE Ratio (13.60) = Dated Quote Price ($46.64) / Consensus Forward EPS ($3.43)
FORWARD PE RATIO
13.60
SECTOR MEDIAN · HEALTHCARE
19.91
median of 191 covered companies
CURRENT VS SECTOR MEDIAN
-31.69%
vs the sector median at left
Rigel Pharmaceuticals, Inc.
Market Cap
$862.98M
Forward PE Ratio
13.60
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Rigel Pharmaceuticals, Inc. (RIGL) | $862.98M | 13.60 |
| SI-BONE, Inc. (SIBN)vs › | $856.68M | N/A |
| SL Science Holding Ltd (SLBT)vs › | $855.16M | N/A |
| QuidelOrtho Corporation (QDEL)vs › | $849.66M | 16.13 |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $874.76M | N/A |
| Pacific Biosciences of California, Inc. (PACB)vs › | $844.84M | N/A |
| SpyGlass Pharma, Inc. Common Stock (SGP)vs › | $843.97M | N/A |
| Arbutus Biopharma Corp (ABUS)vs › | $882.01M | 6.03 |
| Beta Bionics, Inc. (BBNX)vs › | $840.63M | N/A |
| Odyssey Therapeutics, Inc. (ODTX)vs › | $883.54M | N/A |
Trailing P/E
2.9
reported TTM EPS
Forward P/E
13.6
consensus EPS · fiscal year ending 2026-12-31
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $3.43 implies -79.0% EPS decline vs the reported trailing $16.32.
At the dated quote price of $46.64, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $3.43 | $3.11 – $3.75 | 3 | 13.6x |
| 2027-12-31 | $4.58 | $3.34 – $5.58 | 3 | 10.2x |
| 2028-12-31 | $5.87 | $3.84 – $8.07 | 4 | 7.9x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
